McCarthy Asset Management’s ChemoCentryx, Inc. CCXI Stock Holding History

McCarthy Asset Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-100	Closed	-$3K	–	335
2022 Q1	$3K	Hold	100	–	–	﹤0.01%	266
2021 Q4	$4K	Hold	100	–	–	﹤0.01%	224
2021 Q3	$2K	Hold	100	–	–	﹤0.01%	312
2021 Q2	$1K	Buy	+100	New	+$2.46K	﹤0.01%	392

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

McCarthy Asset Management's CCXI Position: Q2 2022 in Review

McCarthy Asset Management sold out of ChemoCentryx, Inc. (CCXI) in Q2 2022, closing a stake of 100 shares — an estimated $3K sold.

McCarthy Asset Management first reported a position in CCXI in Q2 2021 and held it in 4 quarters. The position peaked at $4K in Q4 2021. 182 funds tracked by Wall St. Rank hold CCXI as of Q2 2022.

McCarthy Asset Management reported no remaining ChemoCentryx, Inc. position as of Q2 2022 after selling out during the quarter.
McCarthy Asset Management sold 100 ChemoCentryx, Inc. shares in Q2 2022, an estimated $3K.
McCarthy Asset Management first reported a position in ChemoCentryx, Inc. in Q2 2021 and held it in 4 quarters.
McCarthy Asset Management's ChemoCentryx, Inc. position peaked at $4K in Q4 2021.
182 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2022.

Based on McCarthy Asset Management's 13F filing for Q2 2022, filed 20 Jul 2022.